EcoDrugPlus

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSCVAG00000018163
Gene Symbol: MAPK1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSCVAG00000016168
Gene Symbol: LOC107101186
3 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSCVAG00000016276
Gene Symbol: MAPK10
3 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSCVAG00000013003
Gene Symbol: MAPK11
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSCVAG00000008198
Gene Symbol: MAPK14
3 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a-Like

Ensembl ID : ENSCVAG00000012848
Gene Symbol: LOC107087504
3 Cross references
167 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSCVAG00000003581
Gene Symbol: MAPK8
4 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSCVAG00000004954
Gene Symbol: LOC107101533
3 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSCVAG00000020130
Gene Symbol: MAPK9
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSCVAG00000006038
Gene Symbol: MAP2K1
3 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSCVAG00000017585
Gene Symbol: MAP2K2
3 Cross references
218 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSCVAG00000004957
Gene Symbol: MAP3K10
3 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).